Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection

Systematic Review: T-Cell–based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update

(2013) Madhukar Pai et al.   ANNALS OF INTERNAL MEDICINE

Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection

(2013) Dick Menzies et al.   ANNALS OF INTERNAL MEDICINE

Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort

(2009) Jonathan E Golub et al.   AIDS

Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection

(2009) David P. Holland et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement

(2009) U. Mack et al.   EUROPEAN RESPIRATORY JOURNAL

Isoniazid or Moxifloxacin in Rifapentine-based Regimens for Experimental Tuberculosis?

(2008) Ian M. Rosenthal et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis

(2008) Marcus A. Horwitz et al.   VACCINE